PARP inhibitorFDA-approvedSecond-line
Rucaparib
How it works
Blocks the enzyme that helps repair damaged DNA, making it harder for cancer cells to grow and divide.
Cancer types
Prostate Cancer— Patients with BRCA1 or BRCA2 mutations
Ovarian Cancer— BRCA-mutated
Efficacy
Rucaparib has been shown to improve progression-free survival in BRCA1/2-mutated ovarian cancer patients, with a median progression-free survival of approximately 10 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rucaparib's Effectiveness in Recurrent Ovarian Cancer | Ovarian Cancer | meta-analysis | The pooled objective response rate (ORR) was 0.331 (95% CI, 0.221-0.449; I2 = 92.4%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.